biostudies-literaturePandey ANCATS NIH HHSNIA NIH HHSNHLBI NIH HHS215-223https://www.ebi.ac.uk/biostudies/studies/S-EPMC11229674biostudies-literatureUnknown9(3)<h4>Objectives</h4>This study evaluated the application of a biomarker-based risk score to identify individuals with dysglycemia who are at high risk for incident heart failure (HF) and to inform allocation of effective preventive interventions.<h4>Background</h4>Risk stratification tools to identify patients with diabetes and pre-diabetes at highest risk for HF are needed to inform cost-effective allocation of preventive therapies. Whether a biomarker score can meaningfully stratify HF risk is unknown.<h4>Methods</h4>Participants free of cardiovascular disease from 3 cohort studies (ARIC [Atherosclerosis Risk In Communities], DHS [Dallas Heart Study], and MESA [Multi-Ethnic Study of Atherosclerosis]) were included. An integer-based biomarker score included high-sensitivity cardiac troponiJACC. Heart failureBiomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes.PMC11229674HHSN268201100011IR03 AG067960UL1 TR001105N01HC95159HHSN268201100009IHHSN268201100005CHHSN268201100007CHHSN268201100009CHHSN268201100011CR01 HL071739HHSN268201100005IHHSN268201100005GHHSN268201100007IN01HC95160N01HC95161UL1 TR002541N01HC95162N01HC95163N01HC95164N01HC95165N01HC95169HHSN268201100006CHHSN268201100008CT32 HL125247HHSN268201100010CHHSN268201100008IHHSN268201100012CEverett BMKhan SSde Lemos JAAyers CBallantyne CMPatel KVMcGuire DKVaduganathan MCarnethon MCaughey MCPandey AKosiborod MNDeFilippi CfalseBiomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes.<h4>Objectives</h4>This study evaluated the application of a biomarker-based risk score to identify individuals with dysglycemia who are at high risk for incident heart failure (HF) and to inform allocation of effective preventive interventions.<h4>Background</h4>Risk stratification tools to identify patients with diabetes and pre-diabetes at highest risk for HF are needed to inform cost-effective allocation of preventive therapies. Whether a biomarker score can meaningfully stratify HF risk is unknown.<h4>Methods</h4>Participants free of cardiovascular disease from 3 cohort studies (ARIC [Atherosclerosis Risk In Communities], DHS [Dallas Heart Study], and MESA [Multi-Ethnic Study of Atherosclerosis]) were included. An integer-based biomarker score included high-sensitivity cardiac troponi2021-01-01T00:00:00Z2021 Mar2025-04-04T11:24:31.876Z2025-04-04T11:24:31.876ZS-EPMC112296743342243410.1016/j.jchf.2020.10.013